ClinicalTrials.gg
TerminatedNCT00562198Updated Jun 16, 2008

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding

A Phase 2 interventional study of entacapone and carbidopa and Sinemet 200mg/50mg in Parkinson´s Disease, sponsored by Orion Corporation, Orion Pharma. Terminated at 5 sites in Finland. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-06-16.

Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment

Why this study was terminated
Illogistical results found in interim evaluation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Parkinson Disease · Orion Corporation, Orion Pharma.

Planned enrollment
10th of 11
16 · median 27
Started
2008
the only one that year
Phase 2
4 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma, this one is the 10th largest by planned enrollment, is the only one that started in 2008, is one of 4 in phase 2, and was the 4th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma is open now. The open studies under Parkinson Disease, anywhere →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Parkinson Disease by Orion Corporation, Orion Pharma as a file.
02

Study summary

This is an open, randomised, active-controlled, 2-period crossover study comparing the effect of single doses of Stalevo 200 and Sinemet on striatal (putamenal and caudate) 11C-raclopride BP in PD patients with wearing-off symptoms. The study consists of 4 visits: a screening visit (visit 1), 2 treatment periods (period 1=visit 2, period 2=visit 3) separated by a minimum wash-out period of at least 3 days, and an end-of-study visit (visit 4). Subjects will be randomly allocated to start the period 1 with a single dose of Stalevo 200 or Sinemet. After the wash-out the study drug on period 2 will be administered according to a crossover design.

03

Conditions studied

  • Parkinson´s Disease

Browse trials for

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with idiopathic Parkinson's disease according to the UK Brain Bank criteria.
  2. Predictable wearing-off symptoms with a response to standard release levodopa/carbidopa (200/50 mg)during the levodopa challenge test lasting for a minimum of 1.5 h and a maximum of 4 h.
  3. The magnitude of response (peak effect) in the levodopa challenge test is at least 30%. The magnitude of response is defined to be the difference between the baseline score and the lowest UPDRS III score during the levodopa challenge test.
  4. Hoehn and Yahr stage of at least 2.0 performed during the "ON" state.
  5. Treatment with at least 4 daily doses of levodopa/dopa decarboxylase inhibitor (DDCI) (± entacapone(Comtess® or Stalevo) with total daily levodopa dose in the range of 400-1200mg.
  6. Unchanged levodopa/DDCI ± entacapone and other antiparkinsonian medication [dopamine agonists,monoamine oxidase B (MAO-B) inhibitor, amantadine and/or anticholinergics with an approved dose], if any, for at least 2 weeks prior to period I.
  7. Written obtained.
  8. Age of 45-80 years, inclusive.

Exclusion criteria

Exclusion Criteria:

  1. Secondary or atypical parkinsonism.
  2. Patients with any unpredictable "OFF"-periods.
  3. Patients with moderate to severe treatment-related peak-dose dyskinesia likely to affect the quality of brain magnetic resonance image (MRI) or positron emission tomography (PET) imaging.
  4. Failure to adequately respond to the levodopa (levodopa/carbidopa 200/50 mg) challenge test with the duration of response lasting less than 1.5 h or more than 4 h.
  5. Presence of a basal ganglia lesion in the MRI image or any other factor(s) that would make MRI or PET imaging likely to be unsatisfactory.
  6. Presence of any ferromagnetic objects that would make brain MRI imaging .
  7. Patients with a history of laboratory abnormality consistent with, or cardiovascular,pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness, which may influence the outcome of the study including the interpretation and usage of MRI and PET images for the study purposes.
  8. History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis, malignant melanoma, narrow-angle glaucoma or pheochromocytoma.
  9. Severe hepatic impairment.
  10. Any abnormal (ECG) finding with clinical relevance.
  11. Female patients of (menstruating or less than 2 years ) if they are not using adequate during the study (defined as hormonal contraception, intrauterine device or surgical sterilization) or female patients who are pregnant or lactating.
  12. Treatment with cabergoline.
  13. Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO inhibitors.
  14. Concomitant treatment with any drugs with antidopaminergic action (e.g. with D2 receptor blocking properties) less than two weeks or within five times the elimination half-life of a given drug prior to the first study drug administration. As an exception, the use of domperidone is allowed.
  15. Current, regular use of any iron preparation that cannot be interrupted for the duration of the study
  16. Patients who are likely to need a rescue dose of levodopa after the withdrawal from their own levodopa/DDCI ± entacapone medication prior to PET imaging.
  17. Known to active study drug substances or to any of the .
  18. Participation in other drug studies within 30 days prior to study entry.
  19. Blood donation or loss of significant amount of blood within 60 days prior to the screening.
  20. Any other condition that in the opinion of the investigator could create a hazard to the subject safety,endanger the study procedures or interfere with the interpretation of study results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    1

    Investigational drug Stalevo 200

    Drug: entacapone and carbidopa · Drug: Sinemet 200mg/50mg

Interventions

  • Drugentacapone and carbidopa

    Drug pages: Entacapone · Carbidopa

    Entacapone 200mg carbidopa 50mg

  • DrugSinemet 200mg/50mg

    Sinemet 200mg/50mg once

06

What researchers measure

Primary outcomes

  1. The difference between the study drugs in change in striatal 11C-raclopride BP.Striatal 11C-raclopride BP will be determined with PET scans performed at baseline and from 2.5 to 3.5 h after the study drug administration.

    Time frame: Post-dosing PET scan

Secondary outcomes

  1. The difference between the study drugs in levodopa mean C2.5- 3.5h.

    Time frame: C 2.5-3.5h

07

Study locations

5 sites
  • Helsinki University Hospital, Department of Neurology
    Helsinki, 00029, Finland
  • Oulu University Hospital, Department of Neurology
    Oulu, 90220, Finland
  • Porin Lääkäritalo
    Pori, 28100, Finland
  • FinnMedi Tutkimus Oy
    Tampere, 33520, Finland
  • CRST
    Turku, 20520, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Feb 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2007
First posted
Nov 21, 2007
Start
Jan 2008
Primary completionActual
Feb 2008
CompletionActual
May 2008
Last update
Jun 16, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00562198
First posted
Nov 21, 2007
Start date
Jan 2008
Primary completion
Feb 2008
Completion
May 2008
Last update
Jun 16, 2008

Study contacts

Juha Rinne, Dr
principal investigator · Turku PET Centre, Turku, Finland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion